US 12,011,163 B2
Prediction of tissue irregularities based on biomarker monitoring
Frederick E. Shelton, IV, Hillsboro, OH (US); Chad E. Eckert, Terrace Park, OH (US); and Jason L. Harris, Lebanon, OH (US)
Assigned to Cilag GmbH International, Zug (CH)
Filed by Cilag GmbH International, Zug (CH)
Filed on Jan. 22, 2021, as Appl. No. 17/156,306.
Prior Publication US 2022/0233191 A1, Jul. 28, 2022
Int. Cl. A61B 17/32 (2006.01); A61B 5/00 (2006.01); A61B 5/0537 (2021.01); A61B 17/068 (2006.01); A61B 17/072 (2006.01); A61B 18/14 (2006.01); A61B 90/00 (2016.01); A61B 5/145 (2006.01); A61B 17/00 (2006.01); A61B 34/00 (2016.01); A61B 34/30 (2016.01)
CPC A61B 17/072 (2013.01) [A61B 5/0537 (2013.01); A61B 5/4839 (2013.01); A61B 5/4878 (2013.01); A61B 17/0686 (2013.01); A61B 17/07207 (2013.01); A61B 18/1445 (2013.01); A61B 90/36 (2016.02); A61B 5/14546 (2013.01); A61B 2017/00026 (2013.01); A61B 2017/07214 (2013.01); A61B 2017/07242 (2013.01); A61B 2017/07285 (2013.01); A61B 34/25 (2016.02); A61B 34/30 (2016.02); A61B 2090/365 (2016.02)] 20 Claims
OG exemplary drawing
 
1. A computing system, the computing system comprising:
a processor configured to at least:
obtain, via at least one sensing system, measurement data associated with at least one patient biomarker;
predict a tissue irregularity complication based on the measurement data associated with the at least one patient biomarker; and
generate an output based on the predicted tissue irregularity complication.